Insights into the Binding of Receptor-Binding Domain (RBD) of SARS-CoV-2 Wild Type and B.1.620 Variant with hACE2 Using Molecular Docking and Simulation Approaches

Abstract

Recently, a new variant, B.1620, with mutations (S477N-E484K) in the spike protein’s receptor-binding domain (RBD) has been reported in Europe. In order to design therapeutic strategies suitable for B.1.620, further studies are required. A detailed investigation of the structural features and variations caused by these substitutions, that is, a molecular level investigation, is essential to uncover the role of these changes. To determine whether and how the binding affinity of ACE2–RBD is affected, we used protein–protein docking and all-atom simulation approaches. Our analysis revealed that B.1.620 binds more strongly than the wild type and alters the hydrogen bonding network. The docking score for the wild type was reported to be −122.6 +/− 0.7 kcal/mol, while for B.1.620, the docking score was −124.9 +/− 3.8 kcal/mol. A comparative binding investigation showed that the wild-type complex has 11 hydrogen bonds and one salt bridge, while the B.1.620 complex has 14 hydrogen bonds and one salt bridge, among which most of the interactions are preserved between the wild type and B.1.620. A dynamic analysis of the two complexes revealed stable dynamics, which corroborated the global stability trend, compactness, and flexibility of the three essential loops, providing a better conformational optimization opportunity and binding. Furthermore, binding free energy revealed that the wild type had a total binding energy of −51.14 kcal/mol, while for B.1.628, the total binding energy was −68.25 kcal/mol. The current findings based on protein complex modeling and bio-simulation methods revealed the atomic features of the B.1.620 variant harboring S477N and E484K mutations in the RBD and the basis for infectivity. In conclusion, the current study presents distinguishing features of B.1.620, which can be used to design structure-based drugs against the B.1.620 variant.

Pyrazolone-type compounds: synthesis andin silicoassessment of antiviral potential against key viral proteins of SARS-CoV-2

“…On the other hand, the binding of some compound to the RBD-ACE2 complex could block the virus spread. 43 Additionally, some pyrazolones were identified as potent inhibitors of angiotensin-converting enzyme (ACE), which has a number of pathological roles. 44 This prompted us to investigate the binding of selected pyrazolones to human ACE2 cell receptors, as well as to the spike RBD-ACE2 complex, with the idea that in such case, the SARS-CoV-2 cell entry and spreading could also be prevented.…”

Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2

“…The mechanism of tighter binding of the SARS-CoV-2 S-protein was studied by using MD simulations and MM/GBSA or MM/PBSA calculations by Xue et al, Jafary et al, Spinello et al., and Bhattacharyya et al Interestingly, MM/PBSA calculations at different temperatures suggested that the SARS-CoV-2 RBD was more resistant to temperature changes than the SARS-CoV RBD . Researchers ran MM/PBSA calculations and found that some mutations on S protein could facilitate stronger interactions with human ACE2. − …”

Identifying potential ligand molecules EGFR mediated TNBC targeting the kinase domain-identification of customized drugs through in silico methods

“…The network analysis focuses on studies with applications in cancer research( 15 ). A molecular docking study could be employed to evaluate the PDI network( 16 ). In 2017, Zeeshan Yousuf et al .…”